What is telpotide? ——Analysis of the core mechanism of the new generation of weight loss drugs

1. What is telpoeptide?

Tirzepatide (trade name Mounjaro ) is a new generation GLP-1 + GIP dual receptor agonist . Originally developed by Eli Lilly for the treatment of type 2 diabetes , it has shown unprecedented weight loss effects in weight management , becoming a breakthrough product in the weight loss drug market in recent years.

Unlike traditional GLP-1 receptor agonists (such as smegglutide Wegovy/Ozempic ), telpolide acts on both GLP-1 and GIP incretin receptors , enhancing its ability to suppress appetite, improve metabolism, and promote fat consumption , thus exhibiting a more prominent effect in weight loss.

📌 Key features:

✅ Dual agonist action ( GLP-1 + GIP ) is more potent than GLP-1 alone.

✅ The weight loss effect is significant ; studies show it can reduce body weight by 22.5% ( SURMOUNT-1 study).

✅ It also improves insulin sensitivity and helps prevent diabetes.

✅ Reduce hunger, decrease food intake , and regulate energy balance.

✅ Delaying gastric emptying and reducing blood sugar fluctuations can help control weight in the long term.

 

2. GLP-1 receptor agonist ( Glucagon-Like Peptide-1 ) : How does it help with weight loss?

GLP-1 is an incretin naturally secreted by the body, released by L cells in the intestine after eating. GLP-1 receptor agonists are a class of drugs that mimic the effects of GLP-1 , primarily aiding in weight loss through the following mechanisms:

🔹 Suppressing appetite : GLP-1 acts on the appetite control center in the hypothalamus of the brain, reducing hunger and naturally reducing food intake .

🔹 Delaying gastric emptying : GLP-1 can reduce gastric motility , allowing food to stay in the stomach for a longer time, resulting in a longer feeling of fullness and reducing the frequency of eating.

🔹 Promotes insulin secretion and lowers blood sugar : GLP-1 mainly promotes insulin secretion after eating , helping the body to better utilize blood sugar and prevent excess energy from being converted into fat for storage.

🔹 Reduce glucagon release : Lowering glucagon levels reduces the release of glucose from the liver, which helps control blood sugar.

Representative drugs of GLP-1 receptor agonists :

🔹 Smegglutinin ( Wegovy/Ozempic )

🔹 Liraglutide ( Saxenda )

🔹 Dulaglutide ( Trulicity )

📌 Comparison of GLP-1 effects between telpokines and smegglutinin
Although semaglutide ( Wegovy ) is also a GLP-1 receptor agonist and has achieved good results in weight loss (average weight loss of 16.9% ), telpoglutide not only acts on the GLP-1 receptor but also activates the GIP receptor , resulting in a stronger metabolic effect.

 

3. GIP receptor agonists ( Glucose-Dependent Insulinotropic Peptide ): How to enhance weight loss effects?

GIP receptor agonists are a unique advantage of telpotetide. Previously, other weight loss drugs (such as smegglutide) only acted on GLP-1 , but the addition of GIP receptor agonists makes telpotetide more powerful in metabolic regulation.

🔹 It promotes insulin secretion (acts only when blood sugar is high, reducing the risk of hypoglycemia).

🔹 Improves insulin sensitivity and reduces insulin resistance (especially suitable for overweight patients and those with metabolic disorders).

🔹 It directly promotes fat breakdown , helps reduce body fat, and increases energy expenditure.

🔹 Reducing inflammation helps lower obesity-related chronic inflammatory responses.

📌 Why do GIP receptor agonists enhance weight loss?

GIP not only enhances the blood sugar-lowering effect of GLP-1 , but also regulates fat metabolism , allowing the body to break down fat more effectively instead of storing excess energy. Therefore, the dual effect of GLP-1 + GIP makes telpoide far more efficient at weight loss than GLP-1 receptor agonists alone .

 

4. How effective is telpolide for weight loss? (Clinical data)

The latest SURMOUNT-1 study ( 2022 ) confirmed the remarkable performance of telpoeptide in weight loss:

📊 Weight loss results after 72 weeks (weight loss % ):

Group	telpoeptide 5mg	10mg of telpolide	telpoeptide 15mg	placebo
Average weight loss	15.0%	21.4%	22.5%	2.4%

💡 Comparison with Smegglutinin ( Wegovy ):

•       Smegglutinin ( Wegovy ) resulted in a maximum weight loss of 16.9% ( STEP-1 study).

•       The 15mg telpotassium group achieved an average weight loss of 22.5% , nearly 5.6% higher than Wegovy.

•       More than 60% of patients experienced weight loss exceeding 20% , far higher than that of currently available GLP-1 drugs.

📌 Conclusion: The weight loss effect of telpolide far exceeds that of GLP-1 monoagonals, making it particularly suitable for users who wish to achieve greater weight loss.

 

5. Who is suitable for telpoeptide?

✅ Overweight / obese individuals ( BMI ≥ 30 ) who wish to lose weight scientifically

✅ BMI ≥ 27 with metabolic diseases (such as hypertension, hyperlipidemia, prediabetes)

✅ People with type 2 diabetes need to control both their blood sugar and weight.

✅ Patients who do not respond well to other GLP-1 drugs (such as smegglutide)

⚠️ Not suitable for:

❌ People with a family history of medullary thyroid carcinoma

❌ Patients with severe gastrointestinal diseases (such as those with severe gastroparesis)

❌ Pregnant women or women planning to conceive (currently lacking safety studies)

 

6. Why is telpolide a breakthrough in the new generation of weight loss drugs?

🔹 A dual agonist of GLP-1 and GIP , providing stronger appetite suppression and enhanced fat metabolism.

🔹 Compared to single GLP-1 inhibitors (such as smegglutinin), it has a stronger weight loss effect (up to 22.5% ).

🔹 Suitable for long-term use, with relatively controllable side effects , especially for people with diabetes and high metabolic risk.

🔹 It has received FDA approval, has comprehensive clinical trial data , and enjoys high market acceptance.

📌 If you are looking for a scientific, safe, and more effective weight loss solution, telpoeptide may be one of the best options available.